Johnson & Johnson (NYSE:JNJ) had its price target upped by investment analysts at Stifel Nicolaus from $142.00 to $145.00 in a research report issued to clients and investors on Wednesday. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 2.24% from the stock’s current price.
A number of other research firms have also commented on JNJ. Jefferies Group raised their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. UBS Group reaffirmed a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research note on Saturday, September 30th. Cowen set a $147.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday, October 6th. Citigroup raised their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective for the company in a research note on Wednesday, December 20th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $146.16.
Shares of Johnson & Johnson (JNJ) opened at $141.83 on Wednesday. The firm has a market cap of $383,930.00, a P/E ratio of 363.67, a P/E/G ratio of 2.77 and a beta of 0.80. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Several institutional investors have recently added to or reduced their stakes in the company. Cambridge Trust Co. raised its holdings in Johnson & Johnson by 0.5% in the 4th quarter. Cambridge Trust Co. now owns 301,797 shares of the company’s stock worth $42,167,000 after acquiring an additional 1,584 shares during the period. Pratt Collard Advisory Partners LLC bought a new position in Johnson & Johnson in the 4th quarter worth $4,006,000. Franklin Parlapiano Turner & Welch LLC raised its holdings in Johnson & Johnson by 1.0% in the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock worth $5,363,000 after acquiring an additional 382 shares during the period. Focused Investors LLC raised its holdings in Johnson & Johnson by 8.4% in the 4th quarter. Focused Investors LLC now owns 1,090,000 shares of the company’s stock worth $152,295,000 after acquiring an additional 84,400 shares during the period. Finally, Northpointe Capital LLC raised its holdings in Johnson & Johnson by 39.2% in the 4th quarter. Northpointe Capital LLC now owns 78,929 shares of the company’s stock worth $11,028,000 after acquiring an additional 22,216 shares during the period. Institutional investors and hedge funds own 65.72% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first posted by American Market News and is the property of of American Market News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/24/johnson-johnson-jnj-price-target-raised-to-145-00.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
